Volume 27, Number 2—February 2021
Research
Rapid Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in Detention Facility, Louisiana, USA, May–June, 2020
, Allison E. James1, Rachel Silver, Mitsuki Koh, Farrell A. Tobolowsky, Sean Simonson, Jeremy A. W. Gold, Rena Fukunaga, Henry Njuguna, Keith Bordelon, Jonathan Wortham, Melissa Coughlin, Jennifer L. Harcourt, Azaibi Tamin, Brett Whitaker, Natalie J. Thornburg, Ying Tao, Krista Queen, Anna Uehara, Clinton R. Paden, Jing Zhang, Suxiang Tong, Danielle Haydel, Ha Tran, Kaylee Kim, Kiva A. Fisher, Mariel Marlow, Jacqueline E. Tate, Reena H. Doshi, Theresa Sokol, and Kathryn G. Curran
Table 3
Symptom status of 143 detained persons at time of testing for SARS-CoV-2 and throughout course of investigation in a correctional facility, Louisiana, USA, May–June 2020*
| Symptom status† | SARS-CoV-2 testing results from first positive test result |
SARS-CoV-2 negative, no. (%) | ||
|---|---|---|---|---|
| SARS-CoV-2 positive, no. (%) | Median Ct values (range)‡ | Culture positive, no. (%)§ | ||
| Presymptomatic | 3 (3) | 30.6 (20.0–31.1) | 2 (8) | NA |
| Symptomatic | 21 (19) | 32.7 (19.7–36.3) | 6 (24) | 8 (25) |
| Postsymptomatic | 27 (24) | 33.2 (25.2–37.5) | 3 (12) | 9 (28) |
| Asymptomatic | 49 (44) | 32.9 (19.8–36.9)¶ | 12 (48)# | 12 (34) |
| Unknown | 11 (10) | 33.1 (25.1–35.7) | 2 (8) | 3 (9) |
| Overall | 111 (78) | 33 (19.7–37.5) | 25 (23) | 32 (22) |
*SARS-CoV-2 testing was conducted by using the Centers for Disease Control and Prevention 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel. The Ct values reported for nucleocapsid protein gene 1 target are shown. Ct, cycle threshold; NA, not applicable; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. †Symptom status at time of first positive test result or throughout the investigation for persons remaining SARS-CoV-2 negative. Presympomatic: at least 1 symptom started after positive test result and no symptoms before positive test result; symptomatic: at least 1 symptom ongoing at time of test result (first positive, or any negative test result); postsymptomatic: at least 1 symptom started before test result (first positive result) or before investigation start date (continuous negative results); asymptomatic: no symptoms before test result (first positive result or before each negative test result); unknown: at least 1 symptom is unknown during at least 1 interview. Symptoms assessed: fever, subjective fever, cough, shortness of breath, chills, myalgia, sore throat, loss of taste or smell, or diarrhea ‡Tukey’s test for significance, p = 0.03. §Viral culture positive for replication-competent virus. ¶One person missing a Ct value on the initial day this person tested positive. #One specimen from an asymptomatic person who was positive by real-time reverse transcription PCR was not submitted for culture.
1These authors contributed equally to this article.